Skip to main content

Advertisement

SpringerLink
Log in

The promise of TRAIL—potential and risks of a novel anticancer therapy

  • Review
  • Published:
Journal of Molecular Medicine Aims and scope Submit manuscript

Abstract

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a promising new anticancer biotherapeutic. As shown by many preclinical studies, TRAIL efficiently induces apoptosis in numerous tumor cell lines but not in the majority of normal cells. However, an increasing number of publications report on a predominance of TRAIL resistance in primary human tumor cells, which require sensitization for TRAIL-induced apoptosis. Sensitization of cancer cells by treatment with chemotherapeutic drugs and irradiation has been shown to restore TRAIL sensitivity in many TRAIL-resistant tumor cells. Accordingly TRAIL treatment has been successfully used in different in vivo models for the treatment of tumors also in combination with chemotherapeutics without significant toxicity. However, some reports demonstrated toxicity of TRAIL alone or in combination with chemotherapeutic drugs in normal cells. This review summarizes data concerning the apoptosis-inducing pathways and efficacy of TRAIL, alone or in combination with chemotherapeutic drugs, in primary cancer cells compared to the unwanted effects of TRAIL treatment on normal tissue. We discuss the different in vitro tumor cell models and the potential of different recombinant forms of TRAIL or agonistic antibodies to TRAIL death receptors. Most preclinical studies show a high efficiency of a combinatorial TRAIL-based therapy in animal models and in primary human ex vivo tumor cells with a low toxicity in normal cells. Accordingly clinical phase I/II studies have begun and will be developed further with caution.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Thorburn A (2004) Death receptor-induced cell killing. Cell Signal 16:139–144

    PubMed  CAS  Google Scholar 

  2. Kelley SK, Ashkenazi A (2004) Targeting death receptors in cancer with Apo2L/TRAIL. Curr Opin Pharmacol 4:333–339

    PubMed  CAS  Google Scholar 

  3. Mayes PA, El-Deiry WS (2006) The complementary roles of the extrinsic and intrinsic apoptotic pathways in promoting the death of cancer cells. Cancer J 12:247–249

    PubMed  CAS  Google Scholar 

  4. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK et al (1995) Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3:673–682

    PubMed  CAS  Google Scholar 

  5. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M et al (1999) Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5:157–163

    PubMed  CAS  Google Scholar 

  6. Walczak H, Krammer PH (2000) The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. Exp Cell Res 256:58–66

    PubMed  CAS  Google Scholar 

  7. Sprick MR, Walczak H (2004) The interplay between the Bcl-2 family and death receptor-mediated apoptosis. Biochim Biophys Acta 1644:125–132

    PubMed  CAS  Google Scholar 

  8. Roth W, Reed JC (2004) FLIP protein and TRAIL-induced apoptosis. Vitam Horm 67:189–206

    PubMed  CAS  Google Scholar 

  9. Golks A, Brenner D, Fritsch C, Krammer PH, Lavrik IN (2005) c-FLIPR, a new regulator of death receptor-induced apoptosis. J Biol Chem 280:14507–14513

    PubMed  CAS  Google Scholar 

  10. Xiao C, Yang BF, Asadi N, Beguinot F, Hao C (2002) Tumor necrosis factor-related apoptosis-inducing ligand-induced death-inducing signaling complex and its modulation by c-FLIP and PED/PEA-15 in glioma cells. J Biol Chem 277:25020–25025

    PubMed  CAS  Google Scholar 

  11. Song JH, Bellail A, Tse MC, Yong VW, Hao C (2006) Human astrocytes are resistant to Fas ligand and tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. J Neurosci 26:3299–3308

    PubMed  CAS  Google Scholar 

  12. Willis SN, Chen L, Dewson G, Wei A, Naik E, Fletcher JI et al (2005) Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev 19:1294–1305

    PubMed  CAS  Google Scholar 

  13. Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG et al (2005) Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 17:393–403

    PubMed  CAS  Google Scholar 

  14. Kim H, Rafiuddin-Shah M, Tu HC, Jeffers JR, Zambetti GP, Hsieh JJ et al (2006) Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies. Nat Cell Biol 8:1348–1358

    PubMed  CAS  Google Scholar 

  15. Wrzesien-Kus A, Smolewski P, Sobczak-Pluta A, Wierzbowska A, Robak T (2004) The inhibitor of apoptosis protein family and its antagonists in acute leukemias. Apoptosis 9:705–715

    PubMed  CAS  Google Scholar 

  16. Duiker EW, Mom CH, de Jong S, Willemse PH, Gietema JA, van der Zee AG et al (2006) The clinical trail of TRAIL. Eur J Cancer 42:2233–2240

    PubMed  CAS  Google Scholar 

  17. Wajant H, Gerspach J, Pfizenmaier K (2005) Tumor therapeutics by design: targeting and activation of death receptors. Cytokine Growth Factor Rev 16:55–76

    PubMed  CAS  Google Scholar 

  18. Wu XX, Ogawa O, Kakehi Y (2004) TRAIL and chemotherapeutic drugs in cancer therapy. Vitam Horm 67:365–383

    PubMed  CAS  Google Scholar 

  19. Mitsiades CS, Treon SP, Mitsiades N, Shima Y, Richardson P, Schlossman R et al (2001) TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood 98:795–804

    PubMed  CAS  Google Scholar 

  20. Gazitt Y (1999) TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cells. Leukemia 13:1817–1824

    PubMed  CAS  Google Scholar 

  21. Clodi K, Wimmer D, Li Y, Goodwin R, Jaeger U, Mann G et al (2000) Expression of tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptors and sensitivity to TRAIL-induced apoptosis in primary B-cell acute lymphoblastic leukaemia cells. Br J Haematol 111:580–586

    PubMed  CAS  Google Scholar 

  22. MacFarlane M, Harper N, Snowden RT, Dyer MJ, Barnett GA, Pringle JH et al (2002) Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia. Oncogene 21:6809–6818

    PubMed  CAS  Google Scholar 

  23. Riccioni R, Pasquini L, Mariani G, Saulle E, Rossini A, Diverio D et al (2005) TRAIL decoy receptors mediate resistance of acute myeloid leukemia cells to TRAIL. Haematologica 90:612–624

    PubMed  CAS  Google Scholar 

  24. Snell V, Clodi K, Zhao S, Goodwin R, Thomas EK, Morris SW et al (1997) Activity of TNF-related apoptosis-inducing ligand (TRAIL) in haematological malignancies. Br J Haematol 99:618–624

    PubMed  CAS  Google Scholar 

  25. Panner A, James CD, Berger MS, Pieper RO (2005) mTOR controls FLIPS translation and TRAIL sensitivity in glioblastoma multiforme cells. Mol Cell Biol 25:8809–8823

    PubMed  CAS  Google Scholar 

  26. Clayer M, Bouralexis S, Evdokiou A, Hay S, Atkins GJ, Findlay DM (2001) Enhanced apoptosis of soft tissue sarcoma cells with chemotherapy: a potential new approach using TRAIL. J Orthop Surg (Hong Kong) 9:19–22

    Google Scholar 

  27. Yagita H, Takeda K, Hayakawa Y, Smyth MJ, Okumura K (2004) TRAIL and its receptors as targets for cancer therapy. Can Sci 95:777–783

    CAS  Google Scholar 

  28. Secchiero P, Vaccarezza M, Gonelli A, Zauli G (2004) TNF-related apoptosis-inducing ligand (TRAIL): a potential candidate for combined treatment of hematological malignancies. Curr Pharm Des 10:3673–3681

    PubMed  CAS  Google Scholar 

  29. Ishimura N, Isomoto H, Bronk SF, Gores GJ (2006) Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells. Am J Physiol Gastrointest Liver Physiol 290:G129–G136

    PubMed  CAS  Google Scholar 

  30. Trauzold A, Siegmund D, Schniewind B, Sipos B, Egberts J, Zorenkov D et al (2006) TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma. Oncogene 25:7434–7439

    PubMed  CAS  Google Scholar 

  31. Strater J, Hinz U, Walczak H, Mechtersheimer G, Koretz K, Herfarth C et al (2002) Expression of TRAIL and TRAIL receptors in colon carcinoma: TRAIL-R1 is an independent prognostic parameter. Clin Cancer Res 8:3734–3740

    PubMed  Google Scholar 

  32. Jonsson G, Paulie S, Grandien A (2003) High level of cFLIP correlates with resistance to death receptor-induced apoptosis in bladder carcinoma cells. Anticancer Res 23:1213–1218

    PubMed  Google Scholar 

  33. McCarthy MM, Sznol M, DiVito KA, Camp RL, Rimm DL, Kluger HM (2005) Evaluating the expression and prognostic value of TRAIL-R1 and TRAIL-R2 in breast cancer. Clin Cancer Res 11:5188–5194

    PubMed  CAS  Google Scholar 

  34. Azuhata T, Scott D, Griffith TS, Miller M, Sandler AD (2006) Survivin inhibits apoptosis induced by TRAIL, and the ratio between survivin and TRAIL receptors is predictive of recurrent disease in neuroblastoma. J Pediatr Surg 41:1431–1440

    PubMed  Google Scholar 

  35. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A (1996) Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 271:12687–12690

    PubMed  CAS  Google Scholar 

  36. Schneider P (2000) Production of recombinant TRAIL and TRAIL receptor: Fc chimeric proteins. Methods Enzymol 322:325–345

    PubMed  CAS  Google Scholar 

  37. Ganten TM, Koschny R, Sykora J, Schulze-Bergkamen H, Buchler P, Haas TL et al (2006) Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs. Clin Cancer Res 12:2640–2646

    PubMed  CAS  Google Scholar 

  38. Sayers TJ, Murphy WJ (2006) Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy. Cancer Immunol Immunother 55:76–84

    PubMed  CAS  Google Scholar 

  39. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA et al (1999) Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104:155–162

    PubMed  CAS  Google Scholar 

  40. Kelley SK, Harris LA, Xie D, Deforge L, Totpal K, Bussiere J et al (2001) Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J Pharmacol Exp Ther 299:31–38

    PubMed  CAS  Google Scholar 

  41. Lawrence D, Shahrokh Z, Marsters S, Achilles K, Shih D, Mounho B et al (2001) Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 7:383–385

    PubMed  CAS  Google Scholar 

  42. Jo M, Kim TH, Seol DW, Esplen JE, Dorko K, Billiar TR et al (2000) Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med 6:564–567

    PubMed  CAS  Google Scholar 

  43. Ichikawa K, Liu W, Zhao L, Wang Z, Liu D, Ohtsuka T et al (2001) Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med 7:954–960

    PubMed  CAS  Google Scholar 

  44. Ozoren N, Kim K, Burns TF, Dicker DT, Moscioni AD, El-Deiry WS (2000) The caspase 9 inhibitor Z-LEHD-FMK protects human liver cells while permitting death of cancer cells exposed to tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res 60:6259–6265

    PubMed  CAS  Google Scholar 

  45. Ozoren N, El-Deiry WS (2002) Defining characteristics of Types I and II apoptotic cells in response to TRAIL. Neoplasia 4:551–557

    PubMed  Google Scholar 

  46. Dunn JC, Tompkins RG, Yarmush ML (1992) Hepatocytes in collagen sandwich: evidence for transcriptional and translational regulation. J Cell Biol 116:1043–1053

    PubMed  CAS  Google Scholar 

  47. Ballet F, Bouma ME, Wang SR, Amit N, Marais J, Infante R (1984) Isolation, culture and characterization of adult human hepatocytes from surgical liver biopsies. Hepatology 4:849–854

    Article  PubMed  CAS  Google Scholar 

  48. Hao C, Song JH, Hsi B, Lewis J, Song DK, Petruk KC et al (2004) TRAIL inhibits tumor growth but is nontoxic to human hepatocytes in chimeric mice. Cancer Res 64:8502–8506

    PubMed  CAS  Google Scholar 

  49. Mori E, Thomas M, Motoki K, Nakazawa K, Tahara T, Tomizuka K et al (2004) Human normal hepatocytes are susceptible to apoptosis signal mediated by both TRAIL-R1 and TRAIL-R2. Cell Death Differ 11:203–207

    PubMed  CAS  Google Scholar 

  50. Liang X, Liu Y, Zhang Q, Gao L, Han L, Ma C et al (2007) Hepatitis B virus sensitizes hepatocytes to TRAIL-induced apoptosis through Bax. J Immunol 178:503–510

    PubMed  CAS  Google Scholar 

  51. Liu YG, Liu SX, Liang XH, Zhang Q, Gao LF, Han LH et al (2007) Blockade of TRAIL pathway ameliorates HBV-induced hepatocyte apoptosis in an acute hepatitis model. Biochem Biophys Res Commun 352:329–334

    PubMed  CAS  Google Scholar 

  52. Mundt B, Wirth T, Zender L, Waltemathe M, Trautwein C, Manns MP et al (2005) Tumour necrosis factor related apoptosis inducing ligand (TRAIL) induces hepatic steatosis in viral hepatitis and after alcohol intake. Gut 54:1590–1596

    PubMed  CAS  Google Scholar 

  53. Mundt B, Kuhnel F, Zender L, Paul Y, Tillmann H, Trautwein C et al (2003) Involvement of TRAIL and its receptors in viral hepatitis. Faseb J 17:94–96

    PubMed  CAS  Google Scholar 

  54. Nitsch R, Bechmann I, Deisz RA, Haas D, Lehmann TN, Wendling U et al (2000) Human brain-cell death induced by tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL). Lancet 356:827–828

    PubMed  CAS  Google Scholar 

  55. Dorr J, Roth K, Zurbuchen U, Deisz R, Bechmann I, Lehmann TN et al (2005) Tumor-necrosis-factor-related apoptosis-inducing-ligand (TRAIL)-mediated death of neurons in living human brain tissue is inhibited by flupirtine-maleate. J Neuroimmunol 167:204–209

    PubMed  Google Scholar 

  56. Hao C, Beguinot F, Condorelli G, Trencia A, Van Meir EG, Yong VW et al (2001) Induction and intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) mediated apotosis in human malignant glioma cells. Cancer Res 61:1162–1170

    PubMed  CAS  Google Scholar 

  57. Leverkus M, Neumann M, Mengling T, Rauch CT, Brocker EB, Krammer PH et al (2000) Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes. Cancer Res 60:553–559

    PubMed  CAS  Google Scholar 

  58. Jansen BJ, Van Ruissen F, Cerneus S, Cloin W, Bergers M, Van Erp PE et al (2003) Tumor necrosis factor related apoptosis inducing ligand triggers apoptosis in dividing but not in differentiating human epidermal keratinocytes. J Invest Dermatol 121:1433–1439

    PubMed  CAS  Google Scholar 

  59. Qin J, Chaturvedi V, Bonish B, Nickoloff BJ (2001) Avoiding premature apoptosis of normal epidermal cells. Nat Med 7:385–386

    PubMed  CAS  Google Scholar 

  60. Qin JZ, Bacon PE, Chaturvedi V, Bonish B, Nickoloff BJ (2002) Pathways involved in proliferating, senescent and immortalized keratinocyte cell death mediated by two different TRAIL preparations. Exp Dermatol 11:573–583

    PubMed  CAS  Google Scholar 

  61. Plasilova M, Zivny J, Jelinek J, Neuwirtova R, Cermak J, Necas E et al (2002) TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasia progenitors. Leukemia 16:67–73

    PubMed  CAS  Google Scholar 

  62. Kim SH, Kim K, Kwagh JG, Dicker DT, Herlyn M, Rustgi AK et al (2004) Death induction by recombinant native TRAIL and its prevention by a caspase 9 inhibitor in primary human esophageal epithelial cells. J Biol Chem 279:40044–40052

    PubMed  CAS  Google Scholar 

  63. Gores GJ, Kaufmann SH (2001) Is TRAIL hepatotoxic? Hepatology 34:3–6

    PubMed  CAS  Google Scholar 

  64. Bretz JD, Mezosi E, Giordano TJ, Gauger PG, Thompson NW, Baker JR Jr (2002) Inflammatory cytokine regulation of TRAIL-mediated apoptosis in thyroid epithelial cells. Cell Death Differ 9:274–286

    PubMed  CAS  Google Scholar 

  65. Ichikawa K, Liu W, Fleck M, Zhang H, Zhao L, Ohtsuka T et al (2003) TRAIL-R2 (DR5) mediates apoptosis of synovial fibroblasts in rheumatoid arthritis. J Immunol 171:1061–1069

    PubMed  CAS  Google Scholar 

  66. Strater J, Walczak H, Pukrop T, Von Muller L, Hasel C, Kornmann M et al (2002) TRAIL and its receptors in the colonic epithelium: a putative role in the defense of viral infections. Gastroenterology 122:659–666

    PubMed  CAS  Google Scholar 

  67. El-Zawahry A, Lu P, White SJ, Voelkel-Johnson C (2006) In vitro efficacy of AdTRAIL gene therapy of bladder cancer is enhanced by trichostatin A-mediated restoration of CAR expression and downregulation of cFLIP and Bcl-XL. Cancer Gene Ther 13:281–289

    PubMed  CAS  Google Scholar 

  68. Bremer E, Kuijlen J, Samplonius D, Walczak H, de Leij L, Helfrich W (2004) Target cell-restricted and -enhanced apoptosis induction by a scFv:sTRAIL fusion protein with specificity for the pancarcinoma-associated antigen EGP2. Int J Cancer 109:281–290

    PubMed  CAS  Google Scholar 

  69. Bremer E, Samplonius D, Kroesen BJ, van Genne L, de Leij L, Helfrich W (2004) Exceptionally potent anti-tumor bystander activity of an scFv:sTRAIL fusion protein with specificity for EGP2 toward target antigen-negative tumor cells. Neoplasia 6:636–645

    PubMed  CAS  Google Scholar 

  70. Bremer E, Samplonius DF, Peipp M, van Genne L, Kroesen BJ, Fey GH et al (2005) Target cell-restricted apoptosis induction of acute leukemic t cells by a recombinant tumor necrosis factor-related apoptosis-inducing ligand fusion protein with specificity for human CD7. Cancer Res 65:3380–3388

    PubMed  CAS  Google Scholar 

  71. Bremer E, Samplonius DF, van Genne L, Dijkstra MH, Kroesen BJ, de Leij LF et al (2005) Simultaneous inhibition of epidermal growth factor receptor (EGFR) signaling and enhanced activation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-mediated apoptosis induction by an scFv:sTRAIL fusion protein with specificity for human EGFR. J Biol Chem 280:10025–10033

    PubMed  CAS  Google Scholar 

  72. Assohou-Luty C, Gerspach J, Siegmund D, Muller N, Huard B, Tiegs G et al (2006) A CD40-CD95L fusion protein interferes with CD40L-induced prosurvival signaling and allows membrane CD40L-restricted activation of CD95. J Mol Med 84:785–797

    PubMed  CAS  Google Scholar 

  73. Buchsbaum DJ, Zhou T, Lobuglio AF (2006) TRAIL receptor-targeted therapy. Future Oncol 2:493–508

    PubMed  CAS  Google Scholar 

  74. Buchsbaum DJ, Zhou T, Grizzle WE, Oliver PG, Hammond CJ, Zhang S et al (2003) Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model. Clin Cancer Res 9:3731–3741

    PubMed  CAS  Google Scholar 

  75. Takeda K, Yamaguchi N, Akiba H, Kojima Y, Hayakawa Y, Tanner JE et al (2004) Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy. J Exp Med 199:437–448

    PubMed  CAS  Google Scholar 

  76. Uno T, Takeda K, Kojima Y, Yoshizawa H, Akiba H, Mittler RS et al (2006) Eradication of established tumors in mice by a combination antibody-based therapy. Nat Med 12:693–698

    PubMed  CAS  Google Scholar 

  77. Pukac L, Kanakaraj P, Humphreys R, Alderson R, Bloom M, Sung C et al (2005) HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. Br J Cancer 92:1430–1441

    PubMed  CAS  Google Scholar 

  78. Garber K (2005) New apoptosis drugs face critical test. Nat Biotechnol 23:409–411

    PubMed  CAS  Google Scholar 

  79. Cretney E, Takeda K, Yagita H, Glaccum M, Peschon JJ, Smyth MJ (2002) Increased susceptibility to tumor initiation and metastasis in tnf-related apoptosis-inducing ligand-deficient mice. J Immunol 168:1356–1361

    PubMed  CAS  Google Scholar 

  80. Sedger LM, Glaccum MB, Schuh JC, Kanaly ST, Williamson E, Kayagaki N et al (2002) Characterization of the in vivo function of TNF-alpha-related apoptosis-inducing ligand, TRAIL/Apo2L, using TRAIL/Apo2L gene-deficient mice. Eur J Immunol 32:2246–2254

    PubMed  CAS  Google Scholar 

  81. Seki N, Hayakawa Y, Brooks AD, Wine J, Wiltrout RH, Yagita H et al (2003) Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis is an important endogenous mechanism for resistance to liver metastases in murine renal cancer. Cancer Res 63:207–213

    PubMed  CAS  Google Scholar 

  82. Wajant H, Pfizenmaier K, Scheurich P (2002) TNF-related apoptosis inducing ligand (TRAIL) and its receptors in tumor surveillance and cancer therapy. Apoptosis 7:449–459

    PubMed  CAS  Google Scholar 

  83. Cretney E, Shanker A, Yagita H, Smyth MJ, Sayers TJ (2006) TNF-related apoptosis-inducing ligand as a therapeutic agent in autoimmunity and cancer. Immunol Cell Biol 84:87–98

    PubMed  CAS  Google Scholar 

  84. Ganten TM, Koschny R, Haas TL, Sykora J, Li-Weber M, Herzer K et al (2005) Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL. Hepatology 42:588–597

    PubMed  CAS  Google Scholar 

  85. Koschny R, Ganten TM, Sykora J, Haas TL, Sprick MR, Kolb A et al (2007) TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer-specific apoptosis within a therapeutic window. Hepatology 45:649–658

    PubMed  CAS  Google Scholar 

  86. Marks PA, Dokmanovic M (2005) Histone deacetylase inhibitors: discovery and development as anticancer agents. Expert Opin Investig Drugs 14:1497–1511

    PubMed  CAS  Google Scholar 

  87. Schuchmann M, Schulze-Bergkamen H, Fleischer B, Schattenberg JM, Siebler J, Weinmann A et al (2006) Histone deacetylase inhibition by valproic acid down-regulates c-FLIP/CASH and sensitizes hepatoma cells towards CD95- and TRAIL receptor-mediated apoptosis and chemotherapy. Oncol Rep 15:227–230

    PubMed  CAS  Google Scholar 

  88. Pathil A, Armeanu S, Venturelli S, Mascagni P, Weiss TS, Gregor M et al (2006) HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL. Hepatology 43:425–434

    PubMed  CAS  Google Scholar 

  89. MacFarlane M, Inoue S, Kohlhaas SL, Majid A, Harper N, Kennedy DB et al (2005) Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1. Cell Death Differ 12:773–782

    PubMed  CAS  Google Scholar 

  90. Inoue S, MacFarlane M, Harper N, Wheat LM, Dyer MJ, Cohen GM (2004) Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies. Cell Death Differ 11(Suppl 2):S193–S206

    PubMed  CAS  Google Scholar 

  91. Nebbioso A, Clarke N, Voltz E, Germain E, Ambrosino C, Bontempo P et al (2005) Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat Med 11:77–84

    PubMed  CAS  Google Scholar 

  92. Nakata S, Yoshida T, Horinaka M, Shiraishi T, Wakada M, Sakai T (2004) Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells. Oncogene 23:6261–6271

    PubMed  CAS  Google Scholar 

  93. Chopin V, Slomianny C, Hondermarck H, Le Bourhis X (2004) Synergistic induction of apoptosis in breast cancer cells by cotreatment with butyrate and TNF-alpha, TRAIL, or anti-Fas agonist antibody involves enhancement of death receptors’ signaling and requires P21(waf1). Exp Cell Res 298:560–573

    PubMed  CAS  Google Scholar 

  94. VanOosten RL, Moore JM, Karacay B, Griffith TS (2005) Histone deacetylase inhibitors modulate renal cell carcinoma sensitivity to TRAIL/Apo-2L-induced apoptosis by enhancing TRAIL-R2 expression. Cancer Biother 4:1104–1112

    CAS  Google Scholar 

  95. Singh TR, Shankar S, Srivastava RK (2005) HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma. Oncogene 24:4609–4623

    PubMed  CAS  Google Scholar 

  96. Inoue S, Twiddy D, Dyer MJ, Cohen GM (2006) Upregulation of TRAIL-R2 is not involved in HDACi mediated sensitization to TRAIL-induced apoptosis. Cell Death Differ 13:2160–2162

    PubMed  CAS  Google Scholar 

  97. MacFarlane M, Kohlhaas SL, Sutcliffe MJ, Dyer MJ, Cohen GM (2005) TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies. Cancer Res 65:11265–11270

    PubMed  CAS  Google Scholar 

  98. Olsson A, Diaz T, Aguilar-Santelises M, Osterborg A, Celsing F, Jondal M et al (2001) Sensitization to TRAIL-induced apoptosis and modulation of FLICE-inhibitory protein in B chronic lymphocytic leukemia by actinomycin D. Leukemia 15:1868–1877

    PubMed  CAS  Google Scholar 

  99. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T et al. (2002) Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. Blood 99:4079–4086

    PubMed  CAS  Google Scholar 

  100. Naka T, Sugamura K, Hylander BL, Widmer MB, Rustum YM, Repasky EA (2002) Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients’ colon tumors grown in SCID mice. Cancer Res 62:5800–5806

    PubMed  CAS  Google Scholar 

  101. Hylander BL, Pitoniak R, Penetrante RB, Gibbs JF, Oktay D, Cheng J et al (2005) The anti-tumor effect of Apo2L/TRAIL on patient pancreatic adenocarcinomas grown as xenografts in SCID mice. J Transl Med 3:22

    PubMed  Google Scholar 

  102. Jalving M, de Jong S, Koornstra JJ, Boersma-van Ek W, Zwart N, Wesseling J et al (2006) TRAIL induces apoptosis in human colorectal adenoma cell lines and human colorectal adenomas. Clin Cancer Res 12:4350–4356

    PubMed  CAS  Google Scholar 

  103. Atkins GJ, Bouralexis S, Evdokiou A, Hay S, Labrinidis A, Zannettino AC et al (2002) Human osteoblasts are resistant to Apo2L/TRAIL-mediated apoptosis. Bone 31:448–456

    PubMed  CAS  Google Scholar 

  104. Evdokiou A, Bouralexis S, Atkins GJ, Chai F, Hay S, Clayer M et al (2002) Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L/TRAIL-induced apoptosis. Int J Cancer 99:491–504

    PubMed  CAS  Google Scholar 

  105. Van Valen F, Fulda S, Schafer KL, Truckenbrod B, Hotfilder M, Poremba C et al (2003) Selective and nonselective toxicity of TRAIL/Apo2L combined with chemotherapy in human bone tumour cells vs normal human cells. Int J Cancer 107:929–940

    PubMed  Google Scholar 

  106. Leverkus M, Sprick MR, Wachter T, Mengling T, Baumann B, Serfling E et al (2003) Proteasome Inhibition Results in TRAIL Sensitization of Primary Keratinocytes by Removing the Resistance-Mediating Block of Effector Caspase Maturation. Mol Cell Biol 23:777–790

    PubMed  CAS  Google Scholar 

  107. Ganten TM, Haas TL, Sykora J, Stahl H, Sprick MR, Fas SC et al (2004) Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs. Cell Death Differ 11(Suppl 1):S86–S96

    PubMed  CAS  Google Scholar 

  108. Hyer ML, Croxton R, Krajewska M, Krajewski S, Kress CL, Lu M et al (2005) Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells. Cancer Res 65:4799–4808

    PubMed  CAS  Google Scholar 

  109. Qin JZ, Xin H, Sitailo LA, Denning MF, Nickoloff BJ (2006) Enhanced killing of melanoma cells by simultaneously targeting Mcl-1 and NOXA. Cancer Res 66:9636–9645

    PubMed  CAS  Google Scholar 

  110. Schulze-Bergkamen H, Brenner D, Krueger A, Suess D, Fas SC, Frey CR et al (2004) Hepatocyte growth factor induces Mcl-1 in primary human hepatocytes and inhibits CD95-mediated apoptosis via Akt. Hepatology 39:645–654

    PubMed  CAS  Google Scholar 

  111. Nguyen DM, Yeow WS, Ziauddin MF, Baras A, Tsai W, Reddy RM et al (2006) The essential role of the mitochondria-dependent death-signaling cascade in chemotherapy-induced potentiation of Apo2L/TRAIL cytotoxicity in cultured thoracic cancer cells: amplified caspase 8 is indispensable for combination-mediated massive cell death. Cancer J 12:257–273

    Article  PubMed  CAS  Google Scholar 

  112. Zhang XD, Nguyen T, Thomas WD, Sanders JE, Hersey P (2000) Mechanisms of resistance of normal cells to TRAIL induced apoptosis vary between different cell types. FEBS Lett 482:193–199

    PubMed  CAS  Google Scholar 

  113. Wu XX, Kakehi Y, Mizutani Y, Nishiyama H, Kamoto T, Megumi Y et al (2003) Enhancement of TRAIL/Apo2L-mediated apoptosis by adriamycin through inducing DR4 and DR5 in renal cell carcinoma cells. Int J Cancer 104:409–417

    PubMed  CAS  Google Scholar 

  114. Qin JZ, Bacon P, Panella J, Sitailo LA, Denning MF, Nickoloff BJ (2004) Low-dose UV-radiation sensitizes keratinocytes to TRAIL-induced apoptosis. J Cell Physiol 200:155–166

    PubMed  CAS  Google Scholar 

  115. Griffith TS, Chin WA, Jackson GC, Lynch DH, Kubin MZ (1998) Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J Immunol 161:2833–2840

    PubMed  CAS  Google Scholar 

  116. Kothny-Wilkes G, Kulms D, Poppelmann B, Luger TA, Kubin M, Schwarz T (1998) Interleukin-1 protects transformed keratinocytes from tumor necrosis factor-related apoptosis-inducing ligand. J Biol Chem 273:29247–29253

    PubMed  CAS  Google Scholar 

  117. Taimr P, Higuchi H, Kocova E, Rippe RA, Friedman S, Gores GJ (2003) Activated stellate cells express the TRAIL receptor-2/death receptor-5 and undergo TRAIL-mediated apoptosis. Hepatology 37:87–95

    PubMed  CAS  Google Scholar 

  118. Nesterov A, Ivashchenko Y, Kraft AS (2002) Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) triggers apoptosis in normal prostate epithelial cells. Oncogene 21:1135–1140

    PubMed  CAS  Google Scholar 

  119. Li JH, Kirkiles-Smith NC, McNiff JM, Pober JS (2003) TRAIL induces apoptosis and inflammatory gene expression in human endothelial cells. J Immunol 171:1526–1533

    PubMed  CAS  Google Scholar 

  120. Griffith TS, Rauch CT, Smolak PJ, Waugh JY, Boiani N, Lynch DH et al (1999) Functional analysis of TRAIL receptors using monoclonal antibodies. J Immunol 162:2597–2605

    PubMed  CAS  Google Scholar 

  121. Chuntharapai A, Dodge K, Grimmer K, Schroeder K, Marsters SA, Koeppen H et al (2001) Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4. J Immunol 166:4891–4898

    PubMed  CAS  Google Scholar 

  122. Ohtsuka T, Buchsbaum D, Oliver P, Makhija S, Kimberly R, Zhou T (2003) Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway. Oncogene 22:2034–2044

    PubMed  CAS  Google Scholar 

  123. Voelkel-Johnson C (2003) An antibody against DR4 (TRAIL-R1) in combination with doxorubicin selectively kills malignant but not normal prostate cells. Cancer Biother 2:283–290

    CAS  Google Scholar 

  124. Motoki K, Mori E, Matsumoto A, Thomas M, Tomura T, Humphreys R et al (2005) Enhanced apoptosis and tumor regression induced by a direct agonist antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2. Clin Cancer Res 11:3126–3135

    PubMed  CAS  Google Scholar 

  125. Di Pietro R, Secchiero P, Rana R, Gibellini D, Visani G, Bemis K et al (2001) Ionizing radiation sensitizes erythroleukemic cells but not normal erythroblasts to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated cytotoxicity by selective up-regulation of TRAIL-R1. Blood 97:2596–2603

    PubMed  Google Scholar 

  126. Wu XX, Kakehi Y, Mizutani Y, Kamoto T, Kinoshita H, Isogawa Y et al (2002) Doxorubicin enhances TRAIL-induced apoptosis in prostate cancer. Int J Oncol 20:949–954

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Apoptosis Regulation, German Cancer Research Center (DKFZ), Heidelberg, Germany

    Ronald Koschny, Henning Walczak & Tom M. Ganten

  2. Department of Gastroenterology, Internal Medicine, University of Heidelberg, INF 410, 69120, Heidelberg, Germany

    Ronald Koschny & Tom M. Ganten

Authors
  1. Ronald Koschny
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Henning Walczak
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tom M. Ganten
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tom M. Ganten.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Koschny, R., Walczak, H. & Ganten, T.M. The promise of TRAIL—potential and risks of a novel anticancer therapy. J Mol Med 85, 923–935 (2007). https://doi.org/10.1007/s00109-007-0194-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00109-007-0194-1

Keywords

Search

Navigation